



November 30, 2017

Dear MiMedx Shareholder:

As you will recall, we have had numerous conversations with you, our shareholders, over the last several years, relative to your frustrations with perceived short selling activity and the resulting volatility in our shares. Over that time, the operational performance of your Company has been stellar. We have met or exceeded our revenue forecasts for 26 of the last 27 quarters, and increased sequential revenue for 27 straight quarters. That is almost seven years! MiMedx has just been selected by *Fortune Magazine* as the 5th fastest growing public company in revenues, profits and shareholder returns, putting us ahead of Facebook and Amazon. There are only a few healthcare companies out of thousands that have a track record of this nature.

I have been told that MiMedx's performance has been so flawless that people think we must be doing something "wrong". In my 36 years of being the Chairman and/or CEO of various publicly traded healthcare companies, I have only known a few companies that performed as well as MiMedx. This can only be accomplished in rare situations, where there is an extremely efficient and effective technology platform with products that are cost effective and very clinically effective. When you combine that with a very experienced and effective management team, you have a very strong combination for success.

This type of business performance does not keep individuals, who make a living predominantly by questioning corporate motives and performance and who might have a genuine interest in honest "free speech", from sometimes questioning issues from a negative standpoint. Those types of "free speech" articles, when highlighting actual facts and not misinformation or negative innuendo, are a valid part of a free financial market. Since 2013, MiMedx has been the subject of some articles of that nature, but generally most had misinformation and negative innuendo when there was no substance or meaningful facts. The proof to that statement is simply our stellar operating performance, as highlighted in *Fortune Magazine*. However, over the last several months, MiMedx has been the subject of an illegal, unscrupulous and massive short sell attack.

RESPONSIBILITY OF PUBLIC COMPANY OFFICERS

I would like to explain the legal responsibilities that public company officers have versus those of the principals of hedge funds and other short sell entities. There are major legal disparities relative to these two groups. This situation needs to be corrected because as it exists today it is very detrimental and unfair to the millions of small shareholders relative to the short selling hedge funds and their wealthy partners.

There are well defined regulations and laws associated with any publications or comments that public company officers make. If facts are misrepresented or are actual lies, the company officials can be restricted from being involved with public companies, can be fined and can go to jail.

Moreover, individuals who are involved with short selling and who promote misinformation and lies, in terms of verbal or published comments, do not have those same laws and regulations that constrain them. Of course, there are other laws that apply, and if they conduct other malfeasance, such as paying federal employees for inside information there are further provisions that subject those persons to liability.

Generally, officers of public companies are responsible for building asset value and the stock price usually follows. To offset that, the SEC has decided that short sellers, who will promote the negative aspects of a business enterprise, do play a role. As long as that is done truthfully and meets other rules, regulations and laws, it contributes to the balance of information available in our financial marketplace.

Where this process becomes unbalanced and very unfair to the millions of small investors is when federal laws and regulations that govern this type of activity are not routinely enforced. That generally means the thousands of smaller shareholders, in a company such as MiMedx, can be hurt financially while the wealthy partners of hedge funds and other groups make illicit profits. Unfortunately, that is what we absolutely believe has happened with MiMedx over the last few years, and in particular, the last few months with the appearance of the various illegal short sellers and their publication “shills”.

ILLEGAL SHORT SELLING

The regulations and laws that short sellers generally violate fall into two categories: (1) short and distort and (2) manipulation.

First, a brief explanation of what legitimate short selling involves. This involves an individual or corporate entity locating shares that can be borrowed, generally through another individual having them in a margin account at a brokerage house. Then they sell them into a “short” status and should pay fees to borrow the shares until they are ready to return them by buying shares in the open market. A transaction of that nature is financially “closed” in the normal two day period just like any other purchase of securities requires.

“Illegal naked short selling” is the illegal practice of selling shares that do not exist, meaning they did not borrow shares before selling them short without any intention of delivering the shares. Many brokerage houses are very lackadaisical in requiring their customers to refrain from this unlawful activity perhaps because there is very little accountability. FINRA, which has responsibility for monitoring and enforcing these laws with broker dealers, apparently has a difficult time with this type of enforcement.

It goes without saying that when someone short sells stock in the market, it puts downward pressure on the stock price. When someone buys shares in the market it puts upward pressure on the stock price. Generally, there is no way to buy shares in the open market without complying with the rules and regulations. However, as we have indicated, there are two ways to manipulate the system on the short sell side. Therefore, the system has become very unbalanced and it is now weighted in favor of the short sellers who have few legal and regulatory constraints

to prevent them from manipulating a stock. This is very detrimental to the small shareholders and even some of the institutional shareholders. Some institutional shareholders look the other way because they view this as an ability to buy the company's shares in an undervalued scenario after short sellers have done their work of reducing valuations and financially benefiting their partners.

The second way that short sellers violate SEC rules and regulations is related to the way that they "manipulate" a stock. In my battle at Matria Healthcare approximately ten years ago, the insider at the Chicago hedge fund told me interesting stories about how the numerous hedge funds all acted in concert. He said when they decide it is time for an attack, it is all very well coordinated so all of their actions are ready before the opening of the market and during the daily trading. It is generally related to a catalytic event, such as a "free press" news release, which is really one of their "skills" doing their bidding.

The SEC rules related to "fraud" make it unlawful

for any person, directly or indirectly, . . . (a) to employ any device, scheme, or artifice to defraud, (b) to make any untrue statement of a material fact or to omit to state a material fact necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading, or (c) to engage in any act, practice, or course of business which operates or would operate as a fraud or deceit upon any person, in connection with the purchase or sale of any security.

The U.S. Supreme Court has described "manipulation" as connoting "intentional or willful conduct designed to deceive or defraud investors by controlling or artificially affecting the price of securities." The SEC, on its website, explains that manipulation may involve a number of techniques to affect the supply of, or demand for, a stock.¹ They include: spreading false or misleading information about a company; improperly limiting the number of publicly-available shares; or rigging quotes, prices or trades to create a false or deceptive picture of the demand for a security. The SEC has often charged unlawful manipulation where multiple parties act in concert to manipulate the price of a security, including by publishing false or misleading information and by trading activity which profits from such deception. The rules are quite clear, and yet a great deal of anecdotal evidence indicates that short sellers violate these rules frequently when they conduct an attack.

I hear complaints from shareholders and others all the time about the way the U.S. stock market is "manipulated", and these individuals do not even know all the facts as we have presented in this document. They just know that something is out of balance. This is one reason why many individual shareholders have gravitated towards investing in Exchange Traded Funds (ETFs) and stock Index Funds. That has changed the dynamics of the market considerably, and generally, the consensus is that this is not beneficial to free market trading and realistic valuations. Also, the "volatility" that short sell attacks create with a stock is disconcerting. It drives investors to

¹ See <https://www.sec.gov/fast-answers/answerstmanipulhtm.html>

the sidelines or to the ETFs and Index Funds. It is a shame we have reached the point where the small individual investor and mutual funds are being injured and manipulated by some short sell transactions that are being accomplished illegally.

One thing that I want you to clearly understand is that our stock price decline is not primarily as a result of all of this fictitious, inaccurate and false media and tweeting. It is my opinion that that type of publicity would have taken our stock price down somewhat, but not to the extent it has been. What has taken our stock price down dramatically is the coordinated illegal daily trading by these hedge funds and individuals participating in this activity. They plan their trading activities in advance of a report being released and then work together to manipulate the price lower on the day it is released. The first step is to “flood the market” with sell orders as soon as a publication has been released, which drives the price lower. This gives the very false impression that the stock price decline is being caused by this new and apparently true information. The declining share price “validates” the publication and scares away buyers. As the number of buyers decreases, the easier it becomes to manipulate the stock still lower using illegal trading schemes such as illegal “naked” short selling, “painting the tape”² by trading with each other, “layering and spoofing”³, and “offering out loud”⁴ large fake sell orders.

Again, please understand clearly that even though there is a horrendous amount of false and contrived negative information, I do not believe it is the primary driver of our stock decline. The primary driver is illegal stock manipulation through the market on certain days. The noisiest and most noticeable activity comes through the publications. However, I certainly think the regulators understand clearly that the daily coordinated trading activity by certain firms on a routine basis that is coordinated with the publication from their “shills” is the cause of the major loss in stock price and corporate valuation.

MATRIA HEALTHCARE EXPERIENCE

Having experienced short sell “wolf packs” and their attacks with my previous companies, I have a good perspective on their tactics and techniques. At my previous company, Matria Healthcare,

² “Painting the Tape” is the illegal practice of traders manipulating the price of a stock by trading it amongst themselves to create the false appearance that large amounts of buying or selling are taking place. To manipulate the price higher they will create the impression that large amounts of buying are taking place and to drive it lower that large amounts of selling are taking place.

³ “Layering” and “Spoofing” are illegal trading techniques used to give a false impression that large amounts of buying or selling of a stock is taking place with the intent to cause the price of the stock to either rise or fall. This is done by entering multiple orders over a set period of time with the intention to cancel them before they are executed. “Layering” is the practice of entering multiple buy or sell orders at prices away from the current market whereas “spoofing” is the practice of entering multiple buy or sell orders at the current market.

⁴ “Offering Out Loud” Large Blocks is the practice of entering large sell orders away from the current market with no intention to execute on these orders. This is designed to frighten away buyers.

we had a group of over a dozen hedge funds that spent a great deal of time driving our stock price down in 2007. They worked with a “short sell publisher” by the name of “Off Wall Street” from Connecticut. I was fortunate enough to have an individual from one of the constituent hedge funds in this “wolf pack” become disgusted with what he saw happening, and he called and confided in me. He passed on some of their corrupt and illegal practices. He started sending me, by fax machine, the reports that this “Off Wall Street” short sell “shill” was publishing and sending to their hedge fund subscribers. Remember, there was very little social media in those days. The reports were full of misinformation and blatant lies. Nevertheless, with each published report, we had additional downward pressure on our stock. Over many months, these particular illegal actions took about \$200 million of market cap away from Matria Healthcare and financially affected thousands of our shareholders.

I contacted one of the most successful law firms in the country who routinely sued Wall Street organizations and developed a case. I then called and asked to speak with the CEO of “Off Wall Street”. I advised him that if he printed another word on Matria Healthcare I was going to file a \$200 million lawsuit against his firm. His comments were not very complimentary, but the next day he “officially published” a document that declared “Off Wall Street” was dropping coverage on Matria Healthcare!

The Matria Healthcare story came to a just conclusion when an announcement was made in January 2008 that the Company was being acquired. The stock jumped approximately 30% in one day, and this particular “wolf pack” of short sellers “had a bad day”.

MIMEDX RECENT EXPERIENCE

MiMedx is now the target of some similar illegal short selling activities. We have carefully gathered information over the years on the increase in our short sell interest, and generally, we have found that these increases tend to relate to actions that only individuals with “misappropriated confidential information” would have known. This happened three different times during the summer of 2013 when one of our competitors was actively attempting to thwart our successes by interacting with three Federal agencies in Washington, D.C. Those initiatives all eventually failed, but there is clear evidence of a buildup of short sell interest in our stock prior to the public release of that information from all three agencies. The SEC recently investigated the hedge fund, Deerfield, for similar activities, which led to a settlement between Deerfield and the SEC.

We believe Deerfield was an early short seller of MiMedx stock. We used to routinely meet with their two healthcare analysts, but we knew that they had a short thesis. They bought shares in two of our very small competitors who reportedly were going to take market share from us. Those two investments turned out dismally.

We have previously mentioned that the same two Deerfield analysts who covered MiMedx were investigated by the SEC for extracting inside information from a CMS employee relative to the changes that were going to be proposed for dialysis reimbursement. Apparently, they shorted several dialysis companies based on that “inside information”. During this same period of time,

these analysts were closely following MiMedx with a short thesis. In the summer of 2013, MiMedx was in the same situation at CMS with having a potential change in the Medicare pricing structure taking place. We witnessed a significant increase in our short position take place several weeks prior to the release of the new reimbursement proposals for skin substitute products. While we have no proof, this could have occurred as the result of a leak from a CMS person as happened with the dialysis pricing changes.

As we moved through 2017, recall the increase in value of our stock from a position of being undervalued to a position of being reasonably valued. If Deerfield or any other short seller was still maintaining their short position in our stock, they suffered huge losses. It is my belief that they attempted to motivate other short sellers into joining them at that point to help stem their losses. That situation gathered momentum as they connected with some of our terminated sales employees with whom we were engaged in a very public legal battle.

SALES EMPLOYEE TERMINATIONS

Now, let me discuss four of the employees who were terminated for cause. The names are readily available, and they include Mike Fox, a former Area Vice President, Jess Kruchoski, a former Regional Sales Director and two former sales personnel, Luke Tornquist and another individual we settled with. At one time, these latter three individuals reported to Mike Fox.

The two individuals who originally made allegations to the Company about corporate malfeasance and were interested in leaving the Company and eliminating their non-compete agreements were Kruchoski and Tornquist. Jess Kruchoski, a former Regional Sales Director, had been gathering information on “supposed” corporate malfeasance for approximately a year by making surreptitious recordings of conversations with various MiMedx employees.

Kruchoski had set up his own private company in 2014 to sell products and competitive products while he was in our employment. He kept that a well-guarded secret from management, and falsely told other members of the sales force that corporate was aware of his activities and had sanctioned them. During this year and a half period where he was violating his non-compete and duty of loyalty to MiMedx, he never brought up any of his so called “channel stuffing” allegations or other malfeasance issues through our effective and easy to access compliance communication lines. Only when he decided it was time that he wanted to extort the Company did those issues come forth.

Within a week of Kruchoski sending an email to me and several executives in November 2016, we received a lengthy letter from a Minneapolis attorney alleging numerous other violations of federal laws and regulations. Eventually, his attorney asked us to come to Minneapolis for a mediation discussion. He requested an exorbitant sum of, in effect, “hush money” from MiMedx and requested a release of these two individuals from their non-compete and other agreements with the Company.

MiMedx’s Board of Directors and Management conducted separate investigations into the allegations. As we pulled in numerous emails and other records, we found out the separate

corporate entities that Jess Kruchoski, Mike Fox, and several other individuals had set up. We believe there was a conspiracy underway with approximately ten individuals to come together in a distributor group and attempt to force the Company to eliminate their non-compete contracts and possibly even to give them a distributorship for our products!

By this point in time, several of these individuals were developing substantial revenues for other companies, including one of our competitors. In addition, they enticed a few others in our sales organization to do the same. Ironically, it was the allegations of Jess Kruchoski and Luke Tornquist that allowed the Company to find evidence of the “side businesses” that several employees (including Kruchoski and Tornquist) were engaged in. The Company began an investigation into the matter and interviewed many employees. Some employees initially represented that they knew nothing about any such “selling on the side” activity. Of course, these were absolute lies.

The majority of the other individuals confessed to the activity, and how they were enticed into the scheme. They stated that they respected the Company greatly, and wanted to remain employed. For those individuals who told the truth and agreed to pay restitution, we allowed them to remain in our sales organization. For those individuals who continued to lie, they were terminated. The four original culprits that were uncovered had lawsuits filed against them.

Due to evidence that we quickly obtained, we found one of the major corporations that they were selling products for and sued them. From that entity, we received documentation of sales commission checks and invoices for products and competitive products.

Incidentally, the primary allegation made by some of these terminated individuals was “channel stuffing”. However, what Fox and Kruchoski actually objected to was being held “accountable” for the forecast they had given relative to the revenues for their area and region. They wanted no responsibility for their previous commitments and did not want corporate executives asking questions about “their” accounts. This oversight issue came to a head when our new “Sales Management System” was further implemented in early 2016, which allowed a detailed review of all accounts. This also placed the “selling on the side” scams at risk of exposure. Their lack of accepting responsibility for their own quarterly commitments resulted in their lack of promotions.

The attorney, Clayton Halunen, who originally made the broad claims on behalf of his clients, Jess Kruchoski and Luke Tornquist, only remained their attorney for about 3 months. We believe he was surprised when we presented the evidence associated with his clients selling products including competitive products on the side while being on MiMedx’s payroll. Since that point in time, Jess Kruchoski has been represented by three different attorneys. Luke Tornquist by two.

In my opinion, MiMedx has been extremely transparent with information to our shareholders relative to our terminated sales employees and their unfounded allegations. We have press releases dated December 15, 2016, December 27, 2016, December 30, 2016, March 1, 2017, August 17, 2017 and September 7, 2017 on this subject. We have kept shareholders very apprised of our civil litigation activities. We have kept shareholders apprised of the conclusions

of the Audit Committee of our Board and their outside legal counsel and our external auditors. In addition, a nationally recognized expert in revenue recognition was engaged to provide additional information to the company.

NEW SHORT SELLER “SHILLS”

Adding still more fuel to the fire are the “shill” publications that are reporting on alleged “facts” about the Company which are not really facts at all, but rather false and misleading information. In August, a supposed subscription-based news service by the name of The Capitol Forum started writing reports on MiMedx that just happened to coincide with short selling attacks on MiMedx. This news service was acting, in our opinion, similarly to the short sell “shill” “Off Wall Street” which was involved with illegal short selling of Matria Healthcare in 2007. We obtained some of The Capital Forum’s direct communications with our shareholders, and that gave us grounds for filing a lawsuit.

When The Capitol Forum published its “news” in August, we responded very quickly with press releases clearly explaining all the innuendos and discrediting its sources. Since that time, other “shills” have entered the scene, including Aurelius Value and Viceroy Research.

Obviously, this recent illegal short selling attack has been a confusing scenario for our shareholders and our employees. Since the individuals and corporate entities who are participating in the illegal short selling activities have not been held very accountable in the past, they are prone to say anything and everything to create false innuendo. The allegations are getting to the point of being “ridiculous”. However, you can be assured that these individuals will continue their “sales spin” in any way possible until they realize that telling lies to government regulators is a federal offense.

Also, I realize that ordinary people do not understand just how corrupt dishonest persons can become. Real truthful facts do not mean anything to individuals who have their own agenda. If those facts do not match their agenda, it does not matter what is truthful or not. What will happen in the MiMedx case is that numerous individuals are going to be held accountable for the first time for this type of unscrupulous behavior that involves stock manipulation.

This has become a classic case, and unfortunately, MiMedx is a “poster child” of what fraudulent stock manipulation really involves. In my opinion, these terminated employees should not be considered credible sources of information because of their history. However, these particular illegal short sellers apparently do not care about credible sources for their information. They will still treat our terminated employees’ stories as fact. See our press release dated September 7, 2017.

PRACTICAL AND PROFESSIONAL SOLUTIONS

Over the months, I have taken numerous phone calls from shareholders asking about various solutions to this problem. In addition, we have had conversations with numerous corporate executives, law firms and regulators on these subjects. We are engaged in several efforts to work

with regulators to counter the illegal manipulation of our stock. We believe that FINRA and the SEC could protect you, our shareholders. Therefore, let me give you our clear understanding of the issues that I believe we face in terms of seeing our stock price return to fair and reasonable values.

First and foremost, FINRA could affect our stock returning to normal volatility by sending out what they call “Blue Sheets” to all of their member broker dealers. This request would require the broker dealers to provide to FINRA all their trading activity on MiMedx between certain dates and delineating their customer’s trades. This information would quickly highlight the illegal “naked” short selling and by which customer, which would provide the necessary transparency for all investors. This request would put these short sellers in a “squeeze” where they would have to start closing out their positions by buying stock in the open market if it had been sold on a “naked” basis. We believe this would cause an immediate and sharp increase in MiMedx stock price, the restoration of normal buying and selling patterns and a significant reduction in the stock’s volatility.

It is our belief that the Company currently has about 15 million shares that are in a “naked” status. Imagine what would happen when, not if, the clearing of any “illegal naked” short positions started. I believe that FINRA is the one agency that could bring this attack against us, or other corporate entities, to quick conclusions. The scrutiny of the “naked” positions as well as the “coordinated” attacks by specific hedge funds and individuals on specific days with the release of specific negative sell reports would also be very revealing. Those types of actions are illegal.

Next, the Securities and Exchange Commission, reacting to information from FINRA or their own, could begin developing an enforcement action in sending out subpoenas. When those subpoenas begin to arrive at these numerous firms that would change the trading activity dramatically. I would expect people to start closing out their short positions at that point.

Those are the two regulatory actions that will quickly affect our stock returning to reasonable valuations. We are not aware of any other regulatory actions that would affect matters as dramatically as these would.

Now, what can the Company do to bring closure to these issues? First, we will have our 2017 audit complete and the press release and 10K filed towards the end of February 2018. Even though MiMedx has had ten years of audited financial statements by reputable accounting firms, some people still do not understand the strengths of those reviews and audits. Perhaps an audit by a Big 4 Auditing Firm rather than a regional firm will help people understand that all of these allegations of financial manipulations are “trumped up” and fraudulent. Of course, that should not have to be the case.

However, the final review and sign off by the Securities and Exchange Commission of their investigation should be the ultimate closure document. As we have stated, we are keeping the SEC intimately informed with data and information flow as these allegations continue to be created. Hopefully, this is expediting the process of their necessary reviews. I empathize with the Commission and their staff because of their having seen and heard all of this unscrupulous

and false “noise”. However, I am certain they are beginning to realize that they are talking to some dishonest and cunning “sales persons”. In terms of the short sellers, I am certain the Commission understands who they are and their motivations.

The final component to bringing this to closure will be our performance. We have clearly signaled our enthusiasm for our operating activity, particularly during 2017. We have highlighted the fact that all of our seven years of hard work have resulted in the development of a very strong asset base that is going to support continued rapid growth of our exciting product lines. Please refer to our 2017 Business Report, which is available on our website, for insights into that asset base.

Now, relative to this most significant allegation of “channel stuffing”, let me add the following. When you have ten years of audited financial statements, you have 26 out of 27 quarters where the Company met or exceeded its revenue estimates, a pristine balance sheet with no debt, strong cash flows which have been used to buy back over \$100 million of the Company’s stock which is about 9% of the Company, you cannot be fraudulently selling product to customers who are not using the product and getting paid for it themselves. If you fraudulently sell product, the cash flow will slow down quickly because customers are not going to pay for product that is not going to be used and for which they will not get paid. This channel stuffing allegation as well as all the numerous other allegations are unfounded. We answer all the relevant allegations that are publicized particularly those that relate to regulations and laws by posting factual information and truthful responses to the section of our website entitled “Short Selling Commentary”.

MiMedx Group has become a “Poster Child” for these unscrupulous activities. This letter should strike a chord with thousands of individuals who should express their disdain for this unbalanced scenario which exists between the long and short sellers and causes this illegal activity. Hopefully, this distain will show up in the private sector, as well as the Washington public sectors.

The Securities and Exchange Commission could make three changes that would bring the majority of this illegal short selling activities under better control. First, they could modify the “uptick rule” to address its current deficiencies. This would reduce trading with the unfair advantage that short sellers have as they conduct an attack because it would eliminate their ability to use a continuous stream of short sell orders to drive the stock price lower and induce panic selling. Having to wait for an “uptick” in price to sell short into, should create breaks in the selling and provide investors a brief opportunity to assess what is really causing the price to drop.

Second, they could require hedge funds and other entities to disclose the shares they hold in a short status just like other reporting parties have to do for the shares that are held in “long” status. This would discourage the illegal naked short selling to some extent.

Third, they could prosecute some short sellers who engage in illegal naked shorting and who collude with others to manipulate a stock. These are the type of issues that should be highlighted to your Congressional Representatives.

The SEC should be encouraged to enforce action against the rather flagrant violators of their regulations related to illegal naked short selling and collusion. If the Commission has the

resources to make examples of these practices, at least the chronic perpetrators begin to understand their risks.

Frankly, after my 36 years of being a public company Chairman and CEO, I am thoroughly disgusted with the way the system has developed. I am hearing that same thing from some of our large shareholders all the way down to our smaller shareholders. It is time that you all stepped out and made your points clear to your legislators and perhaps even the enforcement division of the Securities and Exchange Commission.

I will ask you to be patient, if possible, although I fully understand your frustrations. In order to communicate with MiMedx Group on this subject, we have set up a special email address. Please address all of your comments to me at the Company at this email address: shortissues@mimedx.com. If you have any suggestions or know of individuals who have been hurt by these short sellers who break the rules, please make that point clear so we can contact them.

MiMedx is performing exceptionally well. Our last few press releases should have clearly signaled that fact. We are very blessed to have a wonderful and clinically cost effective product line that is helping thousands and thousands of patients every day. The MiMedx team has a very hard working, motivated and talented group of individuals so we expect the Company's performance to continue.

The purpose of this letter is to keep you informed about what is actually transpiring and is moving our stock around in an abnormal manner which creates the volatility. I also wanted to give you some insight into the actual problems associated with this short selling activity. Remember, short selling accomplished by the rules, regulations and laws is perfectly legitimate and does have some purpose. However, organizations and individuals who are not being held accountable to the same rules and regulations as corporate executives take advantage of that flaw with misinformation and lies that cause these abnormalities and volatility. If you feel strongly about how these activities are very detrimental to the individual shareholders, then speak out. Encourage other people to inform their Congressional Representatives about the problem. Feel free to use this letter as one of your illustrations in making your points.

I hope these comments will help put all of this unproductive activity in full perspective. Again, I thank you as shareholders for your confidence in our management and our inspiring technology platform.

"Pete" Petit

SENATE BANKING COMMITTEE

Republican

Michael Crapo Chairman (R-ID)

Richard C. Shelby (R-AL)

Bob Corker (R-TN)

Patrick J. Toomey (R-PA)

Dean Heller (R-NV)

Tim Scott (R-SC)

Ben Sasse (R-NE)

Tom Cotton (R-AR)

Mike Rounds (R-SD)

David Perdue (R-GA)

Thom Tillis (R-NC)

John Kennedy (R-LA)

Democrat

Sherrod Brown Ranking Member (D-OH)

Jack Reed (D-RI)

Robert Menendez (D-NJ)

Jon Tester (D-MT)

Mark R. Warner (D-VA)

Elizabeth Warren (D-MA)

Heidi Heitkamp (D-ND)

Joe Donnelly (D-IN)

Brian Schatz (D-HI)

Chris Van Hollen (D-MD)

Catherine Cortez Masto (D-NV)

HOUSE FINANCE COMMITTEE

115th CONGRESS

Jeb Hensarling, Texas, <i>Chairman</i>	Ted Budd, North Carolina
Peter T. King, New York	David Kustoff, Tennessee
Edward R. Royce, California	Claudia Tenney, New York
Frank D. Lucas, Oklahoma	Trey Hollingsworth, Indiana
Patrick T. McHenry, North Carolina, <i>Vice Chairman</i>	Maxine Waters, California, <i>Ranking Member</i>
Stevan Pearce, New Mexico	Carolyn B. Maloney, New York
Bill Posey, Florida	Nydia M. Velázquez, New York
Blaine Luetkemeyer, Missouri	Brad Sherman, California
Bill Huizenga, Michigan	Gregory W. Meeks, New York
Sean P. Duffy, Wisconsin	Michael E. Capuano, Massachusetts
Steve Stivers, Ohio	Wm. Lacy Clay, Missouri
Randy Hultgren, Illinois	Stephen F. Lynch, Massachusetts
Dennis A. Ross, Florida	David Scott, Georgia
Robert Pittenger, North Carolina	Al Green, Texas
Ann Wagner, Missouri	Emanuel Cleaver, Missouri
Andy Barr, Kentucky	Gwen Moore, Wisconsin
Keith J. Rothfus, Pennsylvania	Keith Ellison, Minnesota
Luke Messer, Indiana	Ed Perlmutter, Colorado
Scott Tipton, Colorado	James A. Himes, Connecticut
Roger Williams, Texas	Bill Foster, Illinois
Bruce Poliquin, Maine	Daniel T. Kildee, Michigan
Mia Love, Utah	John K. Delaney, Maryland
French Hill, Arkansas	Kyrsten Sinema, Arizona
Tom Emmer, Minnesota	Joyce Beatty, Ohio
Lee M. Zeldin, New York	Denny Heck, Washington
Dave A. Trott, Michigan	Juan Vargas, California
Barry Loudermilk, Georgia	Josh Gottheimer, New Jersey
Alexander X. Mooney, West Virginia	Vicente Gonzalez, Texas
Thomas MacArthur, New Jersey	Charlie Crist, Florida
Warren Davidson, Ohio	Ruben J. Kihuen, Nevada

[This page intentionally left blank]

